Class / Patent application number | Description | Number of patent applications / Date published |
514007000 | Phosphorus containing | 18 |
20080269111 | METHOD OF TREATING DYSLIPIDEMIC DISORDER - The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect. | 10-30-2008 |
20090023633 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 01-22-2009 |
20090023634 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 01-22-2009 |
20090036357 | Azapeptide derivatives - This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir. | 02-05-2009 |
20090069218 | PHARMACEUTICAL COMPOSITIONS COMPRISING CASEIN DERIVED PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles. | 03-12-2009 |
20090069219 | DEUTERIUM-ENRICHED TELAVANCIN - The present application describes deuterium-enriched telavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090099066 | Tissue specific peptide conjugates and methods - Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the group consisting of RXR, RX, RB, and RBR; where R is arginine, B is β-alanine, and each X is independently —C(O)—(CHR | 04-16-2009 |
20090111735 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents - Novel compositions and formulations are disclosed that have use to mitigate or prevent physiologically deleterious side-effects and/or modulate the intracellular balance of oxidized and reduced thioredoxin (Trx) in patients with cancer who are receiving treatment with one or more chemotherapeutic agents. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium (mesna). In addition, methods of administration and kits comprising these novel mesna heteroconjugates are disclosed. | 04-30-2009 |
20090156466 | Characterization of a MEKK binding site and uses thereof - The present invention provides binding motifs, binding sites, peptides, and 14-3-3/MEKK complexes. Also provided are agents reactive with same, pharmaceutical compositions, molecules, and kits comprising same, and methods of producing same. The present invention further provides isolated nucleic acids and constructs comprising same, host cells comprising the constructs, and transgenic non-human animals. Additionally, the present invention provides methods of: (a) facilitating or inhibiting 14-3-3/MEKK interaction, (b) regulating MEKK activity, (c) identifying agents that interact with MEKK or 14-3-3, (d) detecting and monitoring the development of MEKK-mediated conditions, and (e) treating and/or preventing MEKK-mediated conditions. | 06-18-2009 |
20090176694 | Reagents and Methods for Smooth Muscle Therapies - The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. | 07-09-2009 |
20090176695 | Reagents and Methods for Smooth Muscle Therapies - The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. | 07-09-2009 |
20090186808 | Method and Compound for the Treatment of Valvular Disease - A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1. | 07-23-2009 |
20090192076 | RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 07-30-2009 |
20090258819 | Reagents and Methods for Smooth Muscle Therapies - The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. | 10-15-2009 |
20090258820 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES - A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections. | 10-15-2009 |
20090305947 | LIVESTOCK MANAGEMENT FOR IMPROVED REPRODUCTIVE EFFICIENCY - The present invention relates to methods for controlling the reproductive cycles and weaning in livestock, particularly to the use of casein-derived peptides for estrus induction and reduction of anestrus intervals, enabling early weaning without negatively affecting the livestock welfare. The present invention further relates to estrus synchronization in a livestock herd and to livestock management programs. | 12-10-2009 |
20100016215 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R) | 01-21-2010 |
20100160211 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. | 06-24-2010 |